Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17135270rdf:typepubmed:Citationlld:pubmed
pubmed-article:17135270lifeskim:mentionsumls-concept:C0035820lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C0041485lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1514562lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1883221lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1149880lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1710236lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1883204lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1880389lld:lifeskim
pubmed-article:17135270lifeskim:mentionsumls-concept:C1707271lld:lifeskim
pubmed-article:17135270pubmed:issue5lld:pubmed
pubmed-article:17135270pubmed:dateCreated2007-1-29lld:pubmed
pubmed-article:17135270pubmed:abstractTextProtein tyrosine phosphatase 1B (PTP-1B) has been implicated in the regulation of the insulin receptor. Dephosphorylation of the insulin receptor results in decreased insulin signaling and thus decreased glucose uptake. PTP-1B-/- mice have increased insulin sensitivity and are resistant to weight gain when fed a high fat diet, validating PTP-1B as a potential target for the treatment of type 2 diabetes. Many groups throughout the world have been searching for selective inhibitors for PTP-1B, and most of them target inhibitors to PTP-1B-(1-298), the N-terminal catalytic domain of the enzyme. However, the C-terminal domain is quite large and could influence the activity of the enzyme. Using two constructs of PTP-1B and a phosphopeptide as substrate, steady state assays showed that the presence of the C-terminal domain decreased both the Km and the k(cat) 2-fold. Pre-steady state kinetic experiments showed that the presence of the C-terminal domain improved the affinity of the enzyme for a phosphopeptide 2-fold, primarily because the off-rate was slower. This suggests that the C-terminal domain of PTP-1B may contact the phosphopeptide in some manner, allowing it to remain at the active site longer. This could be useful when screening libraries of compounds for inhibitors of PTP-1B. A compound that is able to make contacts with the C-terminal domain of PTP-1B would not only have a modest improvement in affinity but may also provide for specificity over other phosphatases.lld:pubmed
pubmed-article:17135270pubmed:languageenglld:pubmed
pubmed-article:17135270pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135270pubmed:citationSubsetIMlld:pubmed
pubmed-article:17135270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135270pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17135270pubmed:statusMEDLINElld:pubmed
pubmed-article:17135270pubmed:monthFeblld:pubmed
pubmed-article:17135270pubmed:issn0021-9258lld:pubmed
pubmed-article:17135270pubmed:authorpubmed-author:PatelSmita...lld:pubmed
pubmed-article:17135270pubmed:authorpubmed-author:KoehnJamesJlld:pubmed
pubmed-article:17135270pubmed:authorpubmed-author:WennogleLawre...lld:pubmed
pubmed-article:17135270pubmed:authorpubmed-author:PichaKristen...lld:pubmed
pubmed-article:17135270pubmed:authorpubmed-author:MandiyanSreek...lld:pubmed
pubmed-article:17135270pubmed:issnTypePrintlld:pubmed
pubmed-article:17135270pubmed:day2lld:pubmed
pubmed-article:17135270pubmed:volume282lld:pubmed
pubmed-article:17135270pubmed:ownerNLMlld:pubmed
pubmed-article:17135270pubmed:authorsCompleteYlld:pubmed
pubmed-article:17135270pubmed:pagination2911-7lld:pubmed
pubmed-article:17135270pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:meshHeadingpubmed-meshheading:17135270...lld:pubmed
pubmed-article:17135270pubmed:year2007lld:pubmed
pubmed-article:17135270pubmed:articleTitleThe role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding.lld:pubmed
pubmed-article:17135270pubmed:affiliationMetabolic and Cardiovascular Diseases Research, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, USA.lld:pubmed
pubmed-article:17135270pubmed:publicationTypeJournal Articlelld:pubmed
entrez-gene:5770entrezgene:pubmedpubmed-article:17135270lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17135270lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17135270lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17135270lld:pubmed